

Altered metabolism of prostaglandin E₂ in asthma patients with aspirin hypersensitivity

To the Editor A specific regulatory role of prostaglandin E₂ (PGE₂) was postulated in aspirin-induced asthma.¹ Indeed, in this distinct asthma phenotype, several observations have accumulated pointing to depressed PGE₂ production by peripheral blood cells, nasal polyps, and bronchial fibroblasts; diminished EP₂ receptor expression on the inflammatory cells; and the association of EP₂ gene polymorphism with aspirin hypersensitivity.²

We performed inhalation challenge with increasing doses of lysine aspirin² in 14 patients with aspirin-induced asthma and 11 asthmatics who tolerated aspirin well. The mean age of the patients was 44.3 years, and the groups did not differ in their main clinical characteristics. In all subjects, exhaled breath condensates (EBC) were collected at baseline.³ The collection was repeated at the time of appearance of the bronchial symptoms in subjects with aspirin-induced asthma, and when the cumulative dose of 182 mg of aspirin was reached in aspirin-tolerant asthmatics. In EBC samples, PGE₂ and its main metabolite (tetranor-PGEM) were measured using gas chromatography / mass spectrometry (GC/MS) and high-performance liquid chromatography/tandem mass spectrometry

(HPLC/MS/MS), respectively. The results were expressed as raw concentration per 1 ml and as parts per million palmitic acid.³

Aspirin precipitated bronchial reactions in all subjects with aspirin-induced asthma, but in no subjects from the aspirin-tolerant group. At baseline, mean PGE₂ values did not differ between the groups, while tetranor-PGEM was higher in subjects with aspirin-induced asthma compared with the other group ($P < 0.001$). Following aspirin challenge, the mean values remained unchanged (TABLE). The dose of aspirin had no effect on the response of PGE₂ and its metabolite. There was a positive correlation between the levels of PGE₂ and tetranor-PGEM following aspirin challenge only in aspirin-tolerant subjects ($r = 0.93$, $P < 0.001$).

Our results add to the observations on the changes in prostaglandin production in aspirin-induced asthma^{2,4-6} and indicate a rapid catabolism of PGE₂ in the lungs – its rate is 4-fold higher in aspirin-induced than in aspirin-tolerant asthma. The upregulation of the enzymes metabolizing PGE₂ might be related to a specific proinflammatory milieu operating in the bronchi of patients with aspirin-induced asthma.

TABLE Prostaglandin E₂ and tetranor-PGEM values at baseline and following aspirin challenge in patients with aspirin-induced asthma and aspirin-tolerant asthma

	Aspirin-induced asthma		Aspirin-tolerant asthma	
	baseline	challenge	baseline	challenge
PGE ₂ , pg/ml	0.79 (0.59 ± 1.17)	0.93 (0.76 ± 1.37)	1.06 (0.44 ± 3.03)	0.641 (0.55 ± 2.32)
PGE ₂ , parts/million of PA	3.49 (2.47 ± 5.81)	3.97 (3.50 ± 6.59)	2.79 (1.31 ± 12.13)	2.104 (1.45 ± 12.22)
tetranor-PGEM, pg/ml	67.84 (63.25 ± 122.50)	89.70 (59.46 ± 133.60)	25.46 (17.60 ± 36.76)	12.03 (9.82 ± 31.98)
tetranor-PGEM, parts/ million of PA	435.40 ^a (212.40 ± 681.50)	357.40 (218.0 ± 502.40)	92.74 ^a (47.81 ± 106.10)	50.00 (24.23 ± 101.30)

Data are presented as median (25% and 75% percentiles).

a significant differences between the groups at baseline ($P < 0.05$)

Abbreviations: PA – palmitic acid, PGE₂ – prostaglandin E₂

Acknowledgments This work was supported by grant No. N N402 373838 from the Polish Ministry of Science.

Author names and affiliations Lucyna Mastalerz, Jagoda Kumik, Hanna Kasperkiewicz, Marek Kaszuba, Paweł Stręk, Marek Sanak (2nd Department of Internal Diseases, Jagiellonian University Medical College, Kraków, Poland).

Correspondence to: Prof. Lucyna Mastalerz, MD, PhD, II Katedra Chorób Wewnętrznych, Uniwersytet Jagielloński, Collegium Medicum, ul. Skawińska 8, 31-088 Kraków, Poland, phone: +48-12-430-52-66, fax: +48-12-430-51-58, e-mail: lmastalerz@wp.pl.

REFERENCES

- 1 Szczeklik A. Prostaglandin E2 and aspirin-induced asthma. *Lancet*. 1995; 345: 1056.
- 2 Szczeklik A, Nizankowska-Mogilnicka E, Sanak M. Hypersensitivity to Aspirin and Nonsteroidal Anti-Inflammatory Drugs. In: Adkinson NF, Busse WW, Bochner BS, et al., eds. *Middleton's Allergy*, 7th Edition. Elsevier Mosby; 2009: 1227-1243.
- 3 Sanak M, Gielicz A, Nagraba K, et al. Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2010; 878: 1796-1800.
- 4 Picado C, Fernandez-Morata JC, Juan M, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. *Am J Respir Crit Care Med*. 1999; 160: 291-296.
- 5 Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. *Am J Respir Crit Care Med*. 2000; 161: 391-398.
- 6 Higashi N, Mita H, Ono E, et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. *J Allergy Clin Immunol*. 2010; 125: 1084-1091.